反流性食管炎发病机制及诊治进展
摘要
反流性食管炎是临床上常见的疾病,以反酸、烧心(胸骨后烧灼感)为主要临床表现。近年来,许多学者深入研究反流性食管炎的发病机制、诊治方法,并取得一定进展。本文在阐述反流性食管炎发病机制、诊断方法的基础上,对反流性食管炎的治疗方法作综述。
引文
[1]Song EM,Jung HK,Jung JM.The association between reflux esophagitis and psychosocial stress[J].Dig Dis Sci,2013,58(2):471-477.
[2]Yang XJ,Jiang HM,Hou XH,et al.Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life[J].World J Gastroenterol,2015,21(14):4302-4309.
[3]王凤云,唐旭东,刘果,等.胃食管反流病食管外症状表现特点及中医药治疗[J].中国中西医结合杂志,2011,31(5):716-719.
[4]赛红梅,唐艳萍,李蕾.反流性食管炎相关功能蛋白表达研究进展[J].天津医药,2018,46(3):318-323.
[5]陈吉,田燕,杨磊.AT1、Mas在反流性食管炎中的表达及意义[J].胃肠病学和肝病学杂志,2018,27(4):422-427.
[6]El-Serag HB,Hashmi A,Garcia J,et al.Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus:a case-control study[J].Gut,2014,63(2):220-229.
[7]Matsuzaki J,Suzuki H,Kobayakawa M,et al.Association of visceral fat area,smoking,and alcohol consumption with reflux esophagitis and barrett’s esophagus in Japan[J].PLoS One,2015,10(7):e0133865.
[8]祁崇斌,牛小平.胃食管反流病发生的危险因素及治疗进展[J].沈阳医学院学报,2018,20(4):355-360.
[9]Ashktorab H,Entezari O,Nouraie M,et al.Helicobacter pylori protection against reflux esophagitis[J].Dig Dis Sci,2012,57(11):2924-2928.
[10]陈旻湖,侯晓华,肖英莲,等.2014年中国胃食管反流病专家共识意见[J].胃肠病学,2015,20(3):155-168.
[11]Katz PO,Gerson LB,Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J].Am J Gastroenterol,2013,108(3):308-328.
[12]Kasyap AK,Sah SK,Chaudhary S.Clinical spectrum and risk factors associated with asymptomatic erosive esophagitis as determined by Los Angeles classification:a cross-sectional study[J].PLoS One,2018,13(2):e0192739.
[13]庞晓阳.反流性食管炎228例临床分析[J].航空航天医学杂志,2012,23(4):429-430.
[14]毛朝亮,周力.X线钡剂造影和胃镜对食管裂孔疝诊断的对比研究[J].贵阳医学院学报,2012,37(3):291-293.
[15]吴小勇,钱永红.X线检查与胃镜检查在反流性食管炎的诊断对比[J].中国社区医师(医学专业),2012,14(36):220.
[16]Lawenko RM,Lee YY.Evaluation of gastroesophageal reflux disease using the bravo capsule pH system[J].JNeurogastroenterol Motil,2016,22(1):25-30.
[17]Rao NM,Campbell DI,Rao P.Two years’experience of using the Bravo wireless oesophageal pH monitoring system at a single UK tertiary centre[J].Acta Paediatr,2017,106(2):312-315.
[18]林三仁,许国铭,胡品津,等.中国胃食管反流病共识意见[J].胃肠病学,2007,12(4):233-239.
[19]林泳,李瑜元,聂玉强.质子泵抑制剂治疗试验诊断胃食管反流病的价值---荟萃分析[J].广州医学院学报,2006,34(5):40-44.
[20]Hayat JO,Gabieta-Somnez S,Yazaki E,et al.Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease[J].Gut,2015,64(3):373-380.
[21]Hong SJ,Park SH,Moon JS,et al.The benefits of combination therapy with esomeprazole and rebamipide in symptom Improvement in reflux esophagitis:an international multicenter study[J].Gut Liver,2016,10(6):910-916.
[22]张遥,徐凌哲,王婧.奥美拉唑镁肠溶片联合西咪替丁治疗反流性食管炎临床分析[J].河北医药,2015,37(6):879-881.
[23]Abdul-Hussein M,Freeman J,Castell D.Concomitant administration of a histamine2receptor antagonist and proton pump Iinhibitor enhances gastric acid suppression[J].Pharmacotherapy,2015,35(12):1124-1129.
[24]Zhang C,Kwong JS,Yuan RX,et al.Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD:network meta-analysis and GRADEsystem[J].Sci Rep,2017,7:41021.
[25]Oshima T,Miwa H.Potent potassium-competitive acid blockers:a new era for the treatment of acid-related diseases[J].J Neurogastroenterol Motil,2018,24(3):334-344.
[26]Hori Y,Matsukawa J,Takeuchi T,et al.A study comparing the antisecretory effect of TAK-438,a novel potassium-competitive acid blocker,with lansoprazole in animals[J].J Pharmacol Exp Ther,2011,337(3):797-804.
[27]Matsukawa J,Hori Y,Nishida H,et al.A comparative study on the modes of action of TAK-438,a novel potassium-competitive acid blocker,and lansoprazole in primary cultured rabbit gastric glands[J].Biochem Pharmacol,2011,81(9):1145-1151.
[28]Sakurai Y,Nishimura A,Kennedy G,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of sngle rising TAK-438(vonoprazan)doses in healthy male Japanese/non-Japanese subjects[J].Clin Transl Gastroenterol,2015,6:e94.
[29]Hoshino S,Kawami N,Takenouchi N,et al.Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis[J].Digestion,2017,95(2):156-161.
[30]张意兰.46例洛赛克联合西沙比利治疗反流性食管炎的临床观察[J].中外医疗,2013,32(27):112-113.
[31]王晓凤,张明.中西医结合治疗反流性食管炎82例[J].中国中西医结合消化杂志,2013,21(1):41-42.
[32]高乐,魏明,邵明义,等.精神心理因素在反流性食管炎治疗中的影响[J].中医临床研究,2016,8(25):62-63,65.
[33]苏有盛,吴封.黛力新联合莫沙必利-雷贝拉唑治疗反流性食管炎伴焦虑抑郁的疗效观察[J].青岛医药卫生,2018,50(2):88-91.
[34]李沛.护理干预在老年反流性食管炎患者护理中的临床应用[J].航空航天医学杂志,2018,29(3):373-374.
[35]Khan Z,Alastal Y,Khan MA,et al.On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis:a systematic review and meta-analysis[J].Gastroenterol Res Pract,2018,2018:6417526.
[36]王惠玲.雷贝拉唑联合奥美拉唑治疗老年性反流性食管炎的临床疗效观察[J].右江民族医学院学报,2014,36(5):723-724.
[37]崔星华,骆建文,农小芬.不同疗程莫沙必利联合雷贝拉唑对缓解反流性食管炎症状的效果比较[J].右江民族医学院学报,2015,37(3):401-403.
[38]Katz PO,Gerson LB,Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J].Am J Gastroenterol,2013,108(3):308-328.
[39]Triadafilopoulos G.Stretta:a valuable endoscopic treatment modality for gastroesophageal reflux disease[J].World J Gastroenterol,2014,20(24):7730-7738.
[40]Franciosa M,Triadafilopoulos G,Mashimo H.Stretta radiofrequency treatment for GERD:a safe and effective modality[J].Gastroenterol Res Pract,2013,2013(10):783815.
[41]Liang WT,Wu JM,Wang F,et al.Stretta radiofrequency for gastroesophageal reflux disease-related respiratory symptoms:a prospective 5-year study[J].Minerva Chir,2014,69(5):293-299.
[42]艾热夏提·吐洪江,克力木·阿不都热依木.经口不切开胃底折叠术治疗胃食管反流病的研究进展[J].中华胃食管反流病电子杂志,2017,4(2):81-83.
[43]Testoni PA,Testoni S,Mazzoleni G,et al.Long-term efficacy of transoral incisionless fundoplication with Esophyx(Tif 2.0)and factors affecting outcomes in GERDpatients followed for up to 6years:aprospective singlecenter study[J].Surg Endosc,2015,29(9):2770-2780.
[44]Svoboda P,KantorováI,Kozumplík L,et al.Our experience with transoral incisionless plication of gastroesophageal reflux disease:NOTES procedure[J].Hepatogastroenterology,2011,58(109):1208-1213.
[45]Sigterman KE,van Pinxteren B,Bonis PA,et al.Shortterm treatment with proton pump inhibitors,H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease[J].Cochrane Database Syst Rev,2013(5):CD002095.
[46]Rickenbacher N,K9tter T,Kochen MM,et al.Fundoplication versus medical management of gastroesophageal reflux disease:systematic review and meta-analysis[J].Surg Endosc,2014,28(1):143-155.
[2]Yang XJ,Jiang HM,Hou XH,et al.Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life[J].World J Gastroenterol,2015,21(14):4302-4309.
[3]王凤云,唐旭东,刘果,等.胃食管反流病食管外症状表现特点及中医药治疗[J].中国中西医结合杂志,2011,31(5):716-719.
[4]赛红梅,唐艳萍,李蕾.反流性食管炎相关功能蛋白表达研究进展[J].天津医药,2018,46(3):318-323.
[5]陈吉,田燕,杨磊.AT1、Mas在反流性食管炎中的表达及意义[J].胃肠病学和肝病学杂志,2018,27(4):422-427.
[6]El-Serag HB,Hashmi A,Garcia J,et al.Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus:a case-control study[J].Gut,2014,63(2):220-229.
[7]Matsuzaki J,Suzuki H,Kobayakawa M,et al.Association of visceral fat area,smoking,and alcohol consumption with reflux esophagitis and barrett’s esophagus in Japan[J].PLoS One,2015,10(7):e0133865.
[8]祁崇斌,牛小平.胃食管反流病发生的危险因素及治疗进展[J].沈阳医学院学报,2018,20(4):355-360.
[9]Ashktorab H,Entezari O,Nouraie M,et al.Helicobacter pylori protection against reflux esophagitis[J].Dig Dis Sci,2012,57(11):2924-2928.
[10]陈旻湖,侯晓华,肖英莲,等.2014年中国胃食管反流病专家共识意见[J].胃肠病学,2015,20(3):155-168.
[11]Katz PO,Gerson LB,Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J].Am J Gastroenterol,2013,108(3):308-328.
[12]Kasyap AK,Sah SK,Chaudhary S.Clinical spectrum and risk factors associated with asymptomatic erosive esophagitis as determined by Los Angeles classification:a cross-sectional study[J].PLoS One,2018,13(2):e0192739.
[13]庞晓阳.反流性食管炎228例临床分析[J].航空航天医学杂志,2012,23(4):429-430.
[14]毛朝亮,周力.X线钡剂造影和胃镜对食管裂孔疝诊断的对比研究[J].贵阳医学院学报,2012,37(3):291-293.
[15]吴小勇,钱永红.X线检查与胃镜检查在反流性食管炎的诊断对比[J].中国社区医师(医学专业),2012,14(36):220.
[16]Lawenko RM,Lee YY.Evaluation of gastroesophageal reflux disease using the bravo capsule pH system[J].JNeurogastroenterol Motil,2016,22(1):25-30.
[17]Rao NM,Campbell DI,Rao P.Two years’experience of using the Bravo wireless oesophageal pH monitoring system at a single UK tertiary centre[J].Acta Paediatr,2017,106(2):312-315.
[18]林三仁,许国铭,胡品津,等.中国胃食管反流病共识意见[J].胃肠病学,2007,12(4):233-239.
[19]林泳,李瑜元,聂玉强.质子泵抑制剂治疗试验诊断胃食管反流病的价值---荟萃分析[J].广州医学院学报,2006,34(5):40-44.
[20]Hayat JO,Gabieta-Somnez S,Yazaki E,et al.Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease[J].Gut,2015,64(3):373-380.
[21]Hong SJ,Park SH,Moon JS,et al.The benefits of combination therapy with esomeprazole and rebamipide in symptom Improvement in reflux esophagitis:an international multicenter study[J].Gut Liver,2016,10(6):910-916.
[22]张遥,徐凌哲,王婧.奥美拉唑镁肠溶片联合西咪替丁治疗反流性食管炎临床分析[J].河北医药,2015,37(6):879-881.
[23]Abdul-Hussein M,Freeman J,Castell D.Concomitant administration of a histamine2receptor antagonist and proton pump Iinhibitor enhances gastric acid suppression[J].Pharmacotherapy,2015,35(12):1124-1129.
[24]Zhang C,Kwong JS,Yuan RX,et al.Effectiveness and tolerability of different recommended doses of PPIs and H2RAs in GERD:network meta-analysis and GRADEsystem[J].Sci Rep,2017,7:41021.
[25]Oshima T,Miwa H.Potent potassium-competitive acid blockers:a new era for the treatment of acid-related diseases[J].J Neurogastroenterol Motil,2018,24(3):334-344.
[26]Hori Y,Matsukawa J,Takeuchi T,et al.A study comparing the antisecretory effect of TAK-438,a novel potassium-competitive acid blocker,with lansoprazole in animals[J].J Pharmacol Exp Ther,2011,337(3):797-804.
[27]Matsukawa J,Hori Y,Nishida H,et al.A comparative study on the modes of action of TAK-438,a novel potassium-competitive acid blocker,and lansoprazole in primary cultured rabbit gastric glands[J].Biochem Pharmacol,2011,81(9):1145-1151.
[28]Sakurai Y,Nishimura A,Kennedy G,et al.Safety,tolerability,pharmacokinetics,and pharmacodynamics of sngle rising TAK-438(vonoprazan)doses in healthy male Japanese/non-Japanese subjects[J].Clin Transl Gastroenterol,2015,6:e94.
[29]Hoshino S,Kawami N,Takenouchi N,et al.Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis[J].Digestion,2017,95(2):156-161.
[30]张意兰.46例洛赛克联合西沙比利治疗反流性食管炎的临床观察[J].中外医疗,2013,32(27):112-113.
[31]王晓凤,张明.中西医结合治疗反流性食管炎82例[J].中国中西医结合消化杂志,2013,21(1):41-42.
[32]高乐,魏明,邵明义,等.精神心理因素在反流性食管炎治疗中的影响[J].中医临床研究,2016,8(25):62-63,65.
[33]苏有盛,吴封.黛力新联合莫沙必利-雷贝拉唑治疗反流性食管炎伴焦虑抑郁的疗效观察[J].青岛医药卫生,2018,50(2):88-91.
[34]李沛.护理干预在老年反流性食管炎患者护理中的临床应用[J].航空航天医学杂志,2018,29(3):373-374.
[35]Khan Z,Alastal Y,Khan MA,et al.On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis:a systematic review and meta-analysis[J].Gastroenterol Res Pract,2018,2018:6417526.
[36]王惠玲.雷贝拉唑联合奥美拉唑治疗老年性反流性食管炎的临床疗效观察[J].右江民族医学院学报,2014,36(5):723-724.
[37]崔星华,骆建文,农小芬.不同疗程莫沙必利联合雷贝拉唑对缓解反流性食管炎症状的效果比较[J].右江民族医学院学报,2015,37(3):401-403.
[38]Katz PO,Gerson LB,Vela MF.Guidelines for the diagnosis and management of gastroesophageal reflux disease[J].Am J Gastroenterol,2013,108(3):308-328.
[39]Triadafilopoulos G.Stretta:a valuable endoscopic treatment modality for gastroesophageal reflux disease[J].World J Gastroenterol,2014,20(24):7730-7738.
[40]Franciosa M,Triadafilopoulos G,Mashimo H.Stretta radiofrequency treatment for GERD:a safe and effective modality[J].Gastroenterol Res Pract,2013,2013(10):783815.
[41]Liang WT,Wu JM,Wang F,et al.Stretta radiofrequency for gastroesophageal reflux disease-related respiratory symptoms:a prospective 5-year study[J].Minerva Chir,2014,69(5):293-299.
[42]艾热夏提·吐洪江,克力木·阿不都热依木.经口不切开胃底折叠术治疗胃食管反流病的研究进展[J].中华胃食管反流病电子杂志,2017,4(2):81-83.
[43]Testoni PA,Testoni S,Mazzoleni G,et al.Long-term efficacy of transoral incisionless fundoplication with Esophyx(Tif 2.0)and factors affecting outcomes in GERDpatients followed for up to 6years:aprospective singlecenter study[J].Surg Endosc,2015,29(9):2770-2780.
[44]Svoboda P,KantorováI,Kozumplík L,et al.Our experience with transoral incisionless plication of gastroesophageal reflux disease:NOTES procedure[J].Hepatogastroenterology,2011,58(109):1208-1213.
[45]Sigterman KE,van Pinxteren B,Bonis PA,et al.Shortterm treatment with proton pump inhibitors,H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease[J].Cochrane Database Syst Rev,2013(5):CD002095.
[46]Rickenbacher N,K9tter T,Kochen MM,et al.Fundoplication versus medical management of gastroesophageal reflux disease:systematic review and meta-analysis[J].Surg Endosc,2014,28(1):143-155.